Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-071 专利权人：国科恒泰（北京）医疗科技股份有限公司 国科恒泰（北京）医疗科技股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的《发明专利证书》，具体情况如下： 发明名称：医疗器械产品运营方法及装置 专利号：ZL 2024 1 0695366.9 专利证书号：第 8475226 号 专利类型：发明专利 专利申请日：2024 年 5 月 31 日 授权公告日：2025 年 11 月 14 日 授权公告号：CN 118674371 B 专利权期限：自申请之日起二十年 专利简介： 该发明专利提供一种医疗器械产品运营方法及装置，方法包括：接收医疗器械 运营平台中采控人员发送的停用停售产品状态维护指令，根据停用停售产品状态维 护指令和预设自然语言分析模型确定对应的采购分仓补货需求和与采购分仓补货 需求对应的产品模型类型，并根据采购分仓补货需求和各产品模型类型之间的依赖 关系确定对 ...

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.51% on November 17, with the leading stock, Kaikai Industrial, falling significantly [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the SPD sector included: - Langma Information: closed at 14.57, up 1.75% with a trading volume of 69,100 shares and a turnover of 100 million yuan - Dashi Intelligent: closed at 3.04, up 1.00% with a trading volume of 527,100 shares and a turnover of 160 million yuan - Guoxin Health: closed at 10.05, up 0.60% with a trading volume of 103,900 shares and a turnover of 104 million yuan [1] - Major decliners included: - Kaikai Industrial: closed at 14.83, down 4.14% with a trading volume of 312,500 shares and a turnover of 463 million yuan - Jianfa Zhixin: closed at 34.76, down 3.44% with a trading volume of 137,400 shares and a turnover of 481 million yuan - Yingte Group: closed at 11.85, down 2.79% with a trading volume of 87,300 shares and a turnover of 104 million yuan [2] Capital Flow - The SPD sector saw a net outflow of 244 million yuan from institutional investors, while retail investors contributed a net inflow of 241 million yuan [2] - The detailed capital flow for selected stocks showed: - Guokai Hengtai: net inflow of 7.31 million yuan from institutional investors - Dashi Intelligent: net outflow of 8.11 million yuan from retail investors - Langma Information: net outflow of 1.80 million yuan from retail investors [3]

证券日报网讯 国科恒泰11月13日在互动平台回答投资者提问时表示，公司未开展细胞免疫治疗相关业 务，也未有相关公告披露。同时公司将坚持聚焦主业，继续努力提升核心竞争力，推动公司高质量发 展，实现公司价值与股东价值的共同提升。 （编辑 王雪儿） ...

Group 1 - The core point of the article is the confirmation of the existence of Xiamen Guokai Hengtai Medical Technology Co., Ltd. as a wholly-owned subsidiary of Guokai Hengtai (301370.SZ) [2] - An investor inquired about the relationship between HeFu China and Guokai Hengtai, specifically regarding the doubling of HeFu China's value [2] - Guokai Hengtai responded on the investor interaction platform, affirming the existence of the subsidiary [2]

格隆汇11月13日丨国科恒泰(301370.SZ)在互动平台表示，公司未开展细胞免疫治疗相关业务，也未有 相关公告披露。同时公司将坚持聚焦主业，继续努力提升核心竞争力，推动公司高质量发展，实现公司 价值与股东价值的共同提升。 ...

（文章来源：证券日报） 证券日报网讯国科恒泰11月12日在互动平台回答投资者提问时表示，截至2025年11月10日，公司股东人 数为18，047户。 ...

Core Viewpoint - The company, Guokai Hengtai, is currently in the early research and exploration phase of its third-party manufacturing (CDMO) business in the medical device sector, which has not yet generated substantial revenue and does not impact the current operating performance of the company [1] Group 1 - The CDMO business is still in the preliminary research and exploration stage [1] - There is no significant revenue generated from the CDMO business at this time [1] - The current operating performance of the company is not affected by the CDMO business [1] Group 2 - The company will continue to monitor opportunities in the upstream manufacturing sector [1] - The company aims to steadily advance its related business in line with strategic development needs [1]

Group 1: Investment Value - The company positions itself as a comprehensive digital supply chain service provider for medical devices, moving beyond traditional distribution models [1] - The long-term strategic layout of "1+3+N" focuses on solidifying the core supply chain business while nurturing three new growth engines: digital business, technology transfer, and international expansion [1][2] - Strong partnerships with global companies like Boston Scientific and Medtronic enhance business stability and risk resilience [2] Group 2: Business Development and Market Trends - The Chinese medical device market is expected to grow due to rigid demand, strong policies, disruptive technologies, and a global perspective [4] - The company’s digital platform addresses traditional distribution challenges, ensuring stability and safety in clinical supply under procurement policies [4] - The company aims to provide comprehensive commercialization solutions, enhancing market influence for medical device manufacturers [2] Group 3: Capital Operations and Future Plans - Currently, there are no specific capital operation plans; future actions will depend on market conditions and strategic needs [3] - The company will utilize capital market tools to promote high-quality development when appropriate [3] Group 4: Digital Business and CDMO Progress - The company has achieved 100% online management of business processes and developed a digital solution for manufacturers, distributors, and hospitals [5][6] - The CDMO (Contract Development and Manufacturing Organization) business is still in the exploratory phase and does not currently impact short-term performance [6]

Core Viewpoint - The company, Guoke Hengtai, has recently received a patent certificate from the National Intellectual Property Administration for an invention related to medical device order processing methods and apparatus [2] Summary by Categories Company Announcement - Guoke Hengtai announced the receipt of an invention patent certificate for a medical device order processing method and apparatus [2]